POLYCYTHEMIA VERA SYNDROME-AS A PROTROMBOTHIC STATE

Authors

  • Oana Viola BADULESCU University of Medicine and Pharmacy „Grigore T. Popa”- Iasi
  • Manuela CIOCOIU University of Medicine and Pharmacy „Grigore T. Popa”- Iasi
  • Iris BARARU University of Medicine and Pharmacy „Grigore T. Popa”- Iasi
  • Madalina MOCANU University of Medicine and Pharmacy „Grigore T. Popa”- Iasi
  • Magda BADESCU University of Medicine and Pharmacy „Grigore T. Popa”- Iasi

Keywords:

THROMBOSIS, POLYCYTHEMIA VERA, PROTEIN S

Abstract

The aim of our study was to investigate whether the disorder of coagulation and fibrinolysis factors are mechanisms that contribute to the prothrombotic state in patients with polycythemia vera (PV) syndrome with or without cardiovascular disease (CVD), in order to identify the patients having high risk for thrombotic events. Material and methods: The study comprises 20 patients divided in 2 groups: 10 patients with PV syndrome (PV) and 10 pacients with PV and cardiovascular diseases associated (PV+CVD). The patients were tested by determining three factors of coagulation profile: protein S, free fraction (PS), antithrombin III (AT III) and Protein C (PC). Results: The level of the three parameters were found significantly modified in the both groups (p<0.05); comparing the results between the two groups of patients, in the second group (PV+CVD) the level of the parameters were significantly lower than in the first group (PV). Conclusions: In PV syndrome the risk for thrombosis is also due to the changes in coagulation factors. Patients with associated cardiovascular disease, present a more severe risk for trombothic events, so regarding the disorder of coagulation factors, this represent a major mechanism implicated in the etiology of thrombosis in these categories of patients.

Author Biographies

  • Oana Viola BADULESCU, University of Medicine and Pharmacy „Grigore T. Popa”- Iasi

    Faculty of Medicine
    Department of Pathophysiology

  • Manuela CIOCOIU, University of Medicine and Pharmacy „Grigore T. Popa”- Iasi

    Faculty of Medicine
    Department of Pathophysiology

  • Iris BARARU, University of Medicine and Pharmacy „Grigore T. Popa”- Iasi

    Faculty of Medicine
    Ph.D. student

  • Madalina MOCANU, University of Medicine and Pharmacy „Grigore T. Popa”- Iasi

    Faculty of Medicine
    Ph.D. student

  • Magda BADESCU, University of Medicine and Pharmacy „Grigore T. Popa”- Iasi

    Faculty of Medicine
    Department of Pathophysiology

References

1. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol. 1992; 48: 20-26.
2. Ania BJ, Suman VJ, Sobell JL, et al. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol. 1994; 47: 89-93.
3. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the UK. Hematol Oncol. 1997; 15: 173-189.
4. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol. 2004; 11: 58-64.
5. Streiff MB, Smith B, Spivak J.L. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group. Blood. 2002; 99: 1144-1148.
6. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90: 4031–4138.
7. Moliterno A, Hankins D, Spivak J. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338: 572–580.
8. Badescu M, Ciocoiu M. Fiziopatologie Specială. Editura Karro,Iaşi,; 2003; 334-377.
9. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348: 1201-1214.
10. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia. 2002; 16: 1207-1212.
11. Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, Geissler K. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood. 2003; 102: 224-228.

Additional Files

Published

2018-05-08